We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

101 hedge funds and large institutions have $153M invested in C4 Therapeutics in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

386% more call options, than puts

Call options by funds: $738K | Put options by funds: $152K

132% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 19

50% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 16

31% more capital invested

Capital invested by funds: $117M → $153M (+$35.9M)

8.57% more ownership

Funds ownership: 73.82% → 82.39% (+8.6%)

4% more funds holding

Funds holding: 97 → 101 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
101
Holders Change
+4
Holders Change %
+4.12%
% of All Funds
1.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
24
Increased
44
Reduced
19
Closed
16
Calls
$738K
Puts
$152K
Net Calls
+$586K
Net Calls Change
+$425K

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$22.4M
2
RCM
RA Capital Management
Massachusetts
+$19M
3
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$14.4M
4
Morgan Stanley
Morgan Stanley
New York
+$9.5M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.99M

Top Sellers

1
O
OrbiMed
New York
-$9.07M
2
SCM
Soleus Capital Management
Connecticut
-$7.7M
3
TCM
Tang Capital Management
California
-$2M
4
Millennium Management
Millennium Management
New York
-$1.77M
5
WA
Wasatch Advisors
Utah
-$1.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
VPIM
76
Vanguard Personalized Indexing Management
California
$29.1K +$1.54K +650 +4%
Prudential Financial
77
Prudential Financial
New Jersey
$28.7K +$1.78K +750 +5%
HSBC Holdings
78
HSBC Holdings
United Kingdom
$26.2K – – –
RS
79
R Squared
Hong Kong
$26.1K -$9.96K -4,206 -24%
NLA
80
Northern Lights Advisors
Washington
$24.7K +$30.6K +12,930 New
JG
81
Jain Global
New York
$24.4K +$30.2K +12,762 New
T. Rowe Price Associates
82
T. Rowe Price Associates
Maryland
$24K – – –
NMC
83
Nine Masts Capital
Hong Kong
$21.9K +$27.2K +11,472 New
EI
84
Ethic Inc
New York
$19.6K -$545 -230 -2%
SW
85
Simplicity Wealth
New Jersey
$19.5K -$26 -11 -0.1%
AHL
86
Abel Hall LLC
Louisiana
$19.4K – – –
BCM
87
Bronte Capital Management
Australia
$19.2K +$23.8K +10,033 New
BFAG
88
Blackston Financial Advisory Group
Florida
$19.1K +$23.7K +10,000 New
JP Morgan Chase
89
JP Morgan Chase
New York
$11.4K +$3.59K +1,516 +34%
Mirae Asset Global Investments
90
Mirae Asset Global Investments
South Korea
$8.99K +$4.64K +1,958 +71%
Osaic Holdings
91
Osaic Holdings
Arizona
$8.68K +$33 +14 +0.3%
NS
92
NBC Securities
Alabama
$7.64K +$9.48K +4,000 New
RhumbLine Advisers
93
RhumbLine Advisers
Massachusetts
$5.19K – – –
BNP Paribas Financial Markets
94
BNP Paribas Financial Markets
France
$4.13K -$186K -78,645 -97%
GFM
95
GF Fund Management
China
$3.63K +$1.04K +440 +30%
FDCDDQ
96
Federation des caisses Desjardins du Quebec
Quebec, Canada
$1.91K +$2.37K +1,000 New
Royal Bank of Canada
97
Royal Bank of Canada
Ontario, Canada
$1K -$431K -181,969 -100%
OC
98
Optima Capital
Oregon
$432 +$535 +226 New
Nisa Investment Advisors
99
Nisa Investment Advisors
Missouri
$298 – – –
SS
100
SBI Securities
Japan
$191 -$123 -52 -34%
1 2 3
4
5

CCCC Hedge Fund Activity: Q4 2025 in Review

101 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q4 2025, worth a combined $153M — up 31% from $117M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CCCC positions and 16 closed out — a net gain of 8 holders — while 44 added to existing stakes and 19 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $22.4M. The largest seller was OrbiMed, cutting an estimated $9.07M.

  • 101 institutional investors held C4 Therapeutics (CCCC) as of Q4 2025, up from 97 in Q3 2025.
  • Funds reported $153M of C4 Therapeutics stock for Q4 2025, up 31% quarter-over-quarter.
  • 24 funds opened new C4 Therapeutics positions in Q4 2025 and 16 closed out, a net change of +8 holders.
  • The largest C4 Therapeutics buyer in Q4 2025 was Point72 Asset Management, an estimated $22.4M added.
  • The largest C4 Therapeutics seller in Q4 2025 was OrbiMed, an estimated $9.07M sold.

Based on aggregated 13F filings for Q4 2025.